This report reviews Covid-19 vaccine research, compares the underlying technologies, the use of adjuvants and delivery systems in their application, and provides a perspective on their future direction.
To identify potential anti-SARS-CoV-2 therapeutics, CAS scientists are building machine-learning predictive models to identify novel drug candidates for the viral targets 3 chymotrypsin-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp).
To support ongoing research and development of COVID-19 therapeutics, this report provides an overview of protein targets and corresponding potential drug candidates with bioassay and structure-activity relationship data found in the scientific and patent literature for COVID-19 or related virus infections.
You May Also Be Interested In...
Articles
Protecting and Commercializing the Promise of RNAi
In this article from The Patent Lawyer Magazine, Anne Marie Clark, Senior Search Analyst for CAS, discusses how to avoid patent pitfalls as the market for RNAi-derived therapeutics grows.
Impact of COVID-19: AI and Machine Learning Solutions
As part of the CPhI webinar series, CAS and IQVIA join forces to deliver insights into optimizing Artificial Intelligence and Machine Learning for predictive analytics, clinical trials and drug discovery in response to COVID-19.
Assay Techniques and Test Development for COVID-19 Diagnosis
To provide a better understanding and comparison of the diagnostic tests available in the fight against COVID-19, CAS has produced a report summarizing the basic principles of molecular and serological assays being used in diagnostic tests for SARS-CoV-2. The report highlights recent advancements in testing technologies and provides a high-level view of currently available diagnostic tests.